A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

• Status: Unknown status
• Trial end date: 2021-02-28
• Target enrollment: 0
• Participant gender: All

Summary

A Phase I Pharmacologic Study of CYC140, a polo-like kinase 1 inhibitor, in Patients with Advanced Leukemias or Myelodysplastic Syndromes

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cyclacel Pharmaceuticals, Inc.
• Collaborator: M.D. Anderson Cancer Center

Criteria

Inclusion Criteria:

• Diagnosis of relapsed or refractory advanced leukemias or MDS

• ECOG 0-2

• Adequate renal function

• Adequate liver function

• ≥ 2 weeks from prior chemotherapy, radiation therapy or major surgery

• ≥ 4 weeks from other investigational anticancer therapy

• Agree to practice effective contraception

Exclusion Criteria:

• Known CNS involvement by leukemia

• Currently receiving radiotherapy, biological therapy, or any other investigational agents

• Uncontrolled intercurrent illness

• Pregnant or lactating

• Known to be HIV-positive

• Known active hepatitis B and/ or hepatitis C infection